Developer docs
API playgroundTry for free, no card

Search company profiles

Fluent BioSciences

Full company profile

uuid0000rdl

Namestring
Fluent BioSciences
Legal namestring
Fluent BioSciences
Websiteurl
fluentbio.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Fluent BioSciences is a life-sciences tools company that developed and commercialized PIPseq (Particle-Templated Instant Partitions) technology, a proprietary chemistry for single-cell RNA sequencing that segregates cell mixtures into barcoded partitions using a vortex mixer instead of complex microfluidic instrumentation. The Watertown, Massachusetts-based firm was founded in 2017 and built a product portfolio spanning four scalable kit tiers (T2, T10, T20, T100) supporting 100 to 200,000 cells per reaction with up to 96-plex multiplexing, supported by the PIPseeker analysis software, accessory reagents, nuclei isolation kits, and dedicated starter equipment. Its customer base spans academic research institutions, biotech and pharmaceutical companies, government labs, and hospital/medical centers performing cellular diversity, developmental biology, immunology, neuroscience, and translational research.

In July 2024 Illumina acquired Fluent BioSciences for less than $120 million to fold PIPseq into its multiomics portfolio; Fluent's kits are now sold as Illumina Single Cell 3' RNA Prep kits through Illumina's global direct sales, online, and distributor channels. The platform integrates with Illumina sequencers (NovaSeq X, NovaSeq 6000, NextSeq 1000/2000, NextSeq 550) as well as third-party platforms from Element Biosciences and Singular Genomics, and routes secondary analysis through DRAGEN, BaseSpace Sequence Hub, Partek Flow, and Illumina Connected Multiomics. The company was funded pre-acquisition through NIH SBIR grants and a 2020 equity round led by Illumina Ventures and Samsara BioCapital.

Short descriptiontext

Fluent BioSciences (acquired by Illumina in July 2024) developed PIPseq, a microfluidics-free single-cell RNA sequencing chemistry sold as Illumina Single Cell 3' RNA Prep kits to academic, biotech, pharmaceutical, government, and clinical research laboratories worldwide.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
single-cell RNA sequencing, scRNA-seq kits, transcriptomics reagents, single-cell analysis software, microfluidics-free sequencing
Industry3 codes
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Laboratory Analytical Instruments3826
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Single-Cell RNA Sequencing Reagents
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Single-cell RNA sequencing kits
TypeOne Time License
Description

Sale of Illumina Single Cell 3' RNA Prep kits including T2 (8 samples, 2000 cells/sample), T10 (8 samples, 10000 cells/sample), T20 (4 samples, 20000 cells/sample), and T100 (2 samples, 100000 cells/sample) kits. Revenue generated from reagent kit sales through Illumina's distribution network.

illumina.com
2PIPseeker Software
TypeSubscription Recurring
Description

Data analysis software available for download. Users must register and agree to End User License Agreement to access downloads.

fluentbio.com
3Accessory Products
TypeOne Time License
Description

Sales of accessory products including Illumina Single Cell Unique Dual Indexes, Nuclei Isolation Kit, Supplemental Enrichment and Amplification Kit, and Starter Equipment (Dry Bath, Vortex Mixer)

fluentbio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Illumina Single Cell 3' RNA Prep
Description

Following acquisition by Illumina in July 2024, Fluent BioSciences' PIPseq technology has been rebranded and integrated into Illumina's product portfolio as Illumina Single Cell 3' RNA Prep kits. The product line includes T2, T10, T20, and T100 kits for scalable single-cell RNA sequencing.

illumina.com
Core offering1 text field

Fluent BioSciences develops and sells single-cell RNA sequencing reagent kits and analysis software based on its proprietary PIPseq (Particle-Templated Instant Partitions) technology. The product line includes four kit tiers (T2, T10, T20, T100) supporting 2,000 to 100,000 cells per sample, along with PIPseeker analysis software, multiplexing indexes, nuclei isolation reagents, enrichment kits, and starter equipment such as vortex mixers and dry baths. The platform enables single-cell mRNA capture, barcoding, and library preparation without requiring microfluidic instrumentation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Single-cell analysis scalable from 100 to 200,000 cells in a single reaction
+3 more records
Product overview1 text field

Fluent BioSciences (acquired by Illumina in July 2024) offers a comprehensive single-cell RNA sequencing solution centered on PIPseq (Particle-Templated Instant Partitions) technology. The portfolio includes four kit tiers—T2 (2,000 cells), T10 (10,000 cells), T20 (20,000 cells), and T100 (100,000 cells)—providing scalable throughput from hundreds to hundreds of thousands of cells. The platform uniquely eliminates the need for expensive microfluidic equipment through a vortex-based workflow. Supporting products include PIPseeker analysis software, sample multiplexing indexes (UDI-96), nuclei isolation reagents, and starter equipment. The solution integrates with Illumina sequencers (NovaSeq, NextSeq), Element Biosciences Aviti, and Singular Genomics platforms, analyzed through DRAGEN, BaseSpace Sequence Hub, and Partek Flow software.

Product and service9 records
1Illumina Single Cell 3' RNA Prep T2 Kit
CategorySingle-cell RNA sequencing kit
Description

Entry-level reagent kit for single-cell RNA sequencing, covering 8 samples with up to 2,000 cells per sample. Includes cell capture, library prep reagents, and cDNA synthesis capabilities, designed for academic and biotech researchers new to single-cell workflows.

2Illumina Single Cell 3' RNA Prep T10 Kit
CategorySingle-cell RNA sequencing kit
Description

Mid-throughput reagent kit covering 8 samples with up to 10,000 cells per sample for single-cell RNA sequencing applications in research and translational settings.

3Illumina Single Cell 3' RNA Prep T20 Kit
CategorySingle-cell RNA sequencing kit
Description

High-capacity reagent kit covering 4 samples with up to 20,000 cells per sample, providing enhanced throughput for larger-scale single-cell RNA sequencing studies.

4Illumina Single Cell 3' RNA Prep T100 Kit
CategorySingle-cell RNA sequencing kit
Description

Ultra-high-throughput reagent kit covering 2 samples with up to 100,000 cells per sample, designed for massive-scale single-cell profiling to identify rare cell types in heterogeneous populations.

5PIPseeker Software
CategoryBioinformatics software
Description

Analysis software for single-cell RNA sequencing data that generates standard feature-barcode count matrices, provides summary metrics, diagnostic plots, clustering, and differential gene expression tables. Compatible with Linux, macOS, and Windows and available via download with registration and End User License Agreement acceptance.

6Illumina Single Cell Unique Dual Indexes
CategoryAccessory reagent product
Description

Accessory product providing 96 indexes that enable high-plex pooling of up to 96 samples, allowing multiplexing of more than 8 samples per sequencing run for single-cell workflows.

7Illumina Single Cell Nuclei Isolation Kit
CategoryAccessory reagent product
Description

Optional accessory reagent kit providing reagents for nuclei isolation, washing, and resuspension to enable single nuclei input into the Illumina Single Cell 3' RNA Prep workflow.

8Illumina Single Cell Supplemental Enrichment and Amplification Kit
CategoryAccessory reagent product
Description

Optional accessory reagent kit providing reagents for custom single-cell applications, enabling enrichment of custom RNA tag sequences for expanded multiomic workflows.

9Illumina Single Cell Prep Starter Equipment
CategoryLaboratory equipment
Description

One-time purchase equipment bundle required for the Illumina Single Cell Library Prep workflow, including a vortex mixer engineered for consistent emulsification, a dry bath with heated lid, and accessories for 0.5ml, 1.5ml, and 5ml tubes.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-04-30
Description

Following acquisition, Illumina integrated Fluent BioSciences single-cell RNA sequencing into its TruPath Genome platform launched in Taiwan in April 2026, combining single-cell transcriptomics with whole-genome sequencing.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-07-01
Description

Illumina acquired Fluent BioSciences in July 2024 for less than $120 million to enhance its multiomics portfolio with single-cell technology. The acquisition is part of Illumina's broader strategy to expand in the single-cell sequencing space. Fluent BioSciences products are now sold under Illumina's brand as Illumina Single Cell 3' RNA Prep kits.

Strategic tierCoreTypeTechnology or Integration
Description

Fluent BioSciences received NIH SBIR Phase II grant to commercialize low-cost, high-capacity single-cell RNA sequencing kits enabled by Ultima Genomics' sequencing technology. The partnership combines Fluent BioSciences' PIPseq technology with Ultima Genomics' high-throughput sequencing capabilities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Washington University in St. Louis lab successfully tested Fluent BioSciences' prototype million-cell analysis kits, demonstrating the potential of the technology for high-throughput cellular analysis research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
11CellBio
TypeEmerging player
Description

Emerging single-cell multiomics player with droplet-based workflows for targeted gene expression and proteogenomics, partially overlapping with PIPseq's transcriptomics applications.

TypeDirect peer
Description

Single-cell sequencing company offering microfluidic-free workflows (AccuraCode, Singleron Matrix) targeting similar academic, clinical, and pharma customers as Fluent/PIPseq.

TypeDirect peer
Description

Single-cell RNA sequencing company whose Evercode platform also eliminates microfluidics through combinatorial barcoding. Directly comparable to PIPseq on the microfluidics-free, scalable workflow value proposition.

TypeBroad incumbent
Description

Broader life science tools and ddPCR/droplet technology provider with single-cell adjacencies through the ddSEQ workflow, supplying incumbent alternatives for scRNA-seq sample prep.

TypeBroad incumbent
Description

Now Fluent's parent company, Illumina provides the NovaSeq/NextSeq sequencing platforms and global commercial infrastructure under which PIPseq is sold as Illumina Single Cell 3' RNA Prep.

TypeEmerging player
Description

Early-stage single-cell company developing low-cost, scalable combinatorial indexing-based workflows; directly comparable on the microfluidics-free, cost-accessible thesis.

TypeOthers
Description

Sequencer vendor whose Aviti platform is documented as compatible with PIPseq chemistry. Acts as an enabling ecosystem partner rather than a direct competitor.

TypeDirect peer
Description

Category leader in single-cell sequencing with the Chromium platform, offering microfluidic droplet-based scRNA-seq, multiome, ATAC, and spatial assays. The dominant incumbent Fluent/PIPseq directly competes against on cost, ease-of-use, and scalability.

TypeDirect peer
Description

Single-cell DNA sequencing and multiomics platform (Tapestri) for genomics, particularly oncology. Competes with Fluent in adjacent single-cell applications and shares overlapping pharma/biotech customers.

TypeDirect peer
Description

BD's Rhapsody single-cell analysis platform uses a microwell-based approach to compete with both microfluidic and PIPseq-style workflows. A major strategic competitor for biotech and pharma single-cell deals.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration11 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Fluent BioSciences

Single-Cell RNA Sequencing Reagentsfluentbio.com

Fluent BioSciences (acquired by Illumina in July 2024) developed PIPseq, a microfluidics-free single-cell RNA sequencing chemistry sold as Illumina Single Cell 3' RNA Prep kits to academic, biotech, pharmaceutical, government, and clinical research laboratories worldwide.

What Fluent BioSciences does

Fluent BioSciences is a life-sciences tools company that developed and commercialized PIPseq (Particle-Templated Instant Partitions) technology, a proprietary chemistry for single-cell RNA sequencing that segregates cell mixtures into barcoded partitions using a vortex mixer instead of complex microfluidic instrumentation. The Watertown, Massachusetts-based firm was founded in 2017 and built a product portfolio spanning four scalable kit tiers (T2, T10, T20, T100) supporting 100 to 200,000 cells per reaction with up to 96-plex multiplexing, supported by the PIPseeker analysis software, accessory reagents, nuclei isolation kits, and dedicated starter equipment. Its customer base spans academic research institutions, biotech and pharmaceutical companies, government labs, and hospital/medical centers performing cellular diversity, developmental biology, immunology, neuroscience, and translational research.

In July 2024 Illumina acquired Fluent BioSciences for less than $120 million to fold PIPseq into its multiomics portfolio; Fluent's kits are now sold as Illumina Single Cell 3' RNA Prep kits through Illumina's global direct sales, online, and distributor channels. The platform integrates with Illumina sequencers (NovaSeq X, NovaSeq 6000, NextSeq 1000/2000, NextSeq 550) as well as third-party platforms from Element Biosciences and Singular Genomics, and routes secondary analysis through DRAGEN, BaseSpace Sequence Hub, Partek Flow, and Illumina Connected Multiomics. The company was funded pre-acquisition through NIH SBIR grants and a 2020 equity round led by Illumina Ventures and Samsara BioCapital.

Fluent BioSciences firmographics

Firmographics
Name
Fluent BioSciences
Legal name
Fluent BioSciences
Website
https://fluentbio.com
Company type
Private
Founded year
2017
Operating status
Acquired
Headcount range
1–10 employees
Short description
Fluent BioSciences (acquired by Illumina in July 2024) developed PIPseq, a microfluidics-free single-cell RNA sequencing chemistry sold as Illumina Single Cell 3' RNA Prep kits to academic, biotech, pharmaceutical, government, and clinical research laboratories worldwide.
Ownership category
akta.pro rank

Fluent BioSciences industry classification

Industry
Product category
Single-Cell RNA Sequencing Reagents
NAICS
Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)

Keywords

  • Single-cell RNA sequencing
  • ScRNA-seq kits
  • Transcriptomics reagents
  • Single-cell analysis software
  • Microfluidics-free sequencing

Where Fluent BioSciences is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Fluent BioSciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Single-cell RNA sequencing kits: Sale of Illumina Single Cell 3' RNA Prep kits including T2 (8 samples, 2000 cells/sample), T10 (8 samples, 10000 cells/sample), T20 (4 samples, 20000 cells/sample), and T100 (2 samples, 100000 cells/sample) kits. Revenue generated from reagent kit sales through Illumina's distribution network.
  2. PIPseeker Software: Data analysis software available for download. Users must register and agree to End User License Agreement to access downloads.
  3. Accessory Products: Sales of accessory products including Illumina Single Cell Unique Dual Indexes, Nuclei Isolation Kit, Supplemental Enrichment and Amplification Kit, and Starter Equipment (Dry Bath, Vortex Mixer)

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Fluent BioSciences product offering

Product offering

Core offering

Fluent BioSciences develops and sells single-cell RNA sequencing reagent kits and analysis software based on its proprietary PIPseq (Particle-Templated Instant Partitions) technology. The product line includes four kit tiers (T2, T10, T20, T100) supporting 2,000 to 100,000 cells per sample, along with PIPseeker analysis software, multiplexing indexes, nuclei isolation reagents, enrichment kits, and starter equipment such as vortex mixers and dry baths. The platform enables single-cell mRNA capture, barcoding, and library preparation without requiring microfluidic instrumentation.

Product overview

Fluent BioSciences (acquired by Illumina in July 2024) offers a comprehensive single-cell RNA sequencing solution centered on PIPseq (Particle-Templated Instant Partitions) technology. The portfolio includes four kit tiers—T2 (2,000 cells), T10 (10,000 cells), T20 (20,000 cells), and T100 (100,000 cells)—providing scalable throughput from hundreds to hundreds of thousands of cells. The platform uniquely eliminates the need for expensive microfluidic equipment through a vortex-based workflow. Supporting products include PIPseeker analysis software, sample multiplexing indexes (UDI-96), nuclei isolation reagents, and starter equipment. The solution integrates with Illumina sequencers (NovaSeq, NextSeq), Element Biosciences Aviti, and Singular Genomics platforms, analyzed through DRAGEN, BaseSpace Sequence Hub, and Partek Flow software.

Differentiator

Problem solved

Functional benefit

Brands

  • Illumina Single Cell 3' RNA Prep: Following acquisition by Illumina in July 2024, Fluent BioSciences' PIPseq technology has been rebranded and integrated into Illumina's product portfolio as Illumina Single Cell 3' RNA Prep kits. The product line includes T2, T10, T20, and T100 kits for scalable single-cell RNA sequencing.

Products and services

  • Illumina Single Cell 3' RNA Prep T2 Kit Entry-level reagent kit for single-cell RNA sequencing, covering 8 samples with up to 2,000 cells per sample. Includes cell capture, library prep reagents, and cDNA synthesis capabilities, designed for academic and biotech researchers new to single-cell workflows.
  • Illumina Single Cell 3' RNA Prep T10 Kit Mid-throughput reagent kit covering 8 samples with up to 10,000 cells per sample for single-cell RNA sequencing applications in research and translational settings.
  • Illumina Single Cell 3' RNA Prep T20 Kit High-capacity reagent kit covering 4 samples with up to 20,000 cells per sample, providing enhanced throughput for larger-scale single-cell RNA sequencing studies.
  • Illumina Single Cell 3' RNA Prep T100 Kit Ultra-high-throughput reagent kit covering 2 samples with up to 100,000 cells per sample, designed for massive-scale single-cell profiling to identify rare cell types in heterogeneous populations.
  • PIPseeker Software Analysis software for single-cell RNA sequencing data that generates standard feature-barcode count matrices, provides summary metrics, diagnostic plots, clustering, and differential gene expression tables. Compatible with Linux, macOS, and Windows and available via download with registration and End User License Agreement acceptance.
  • Illumina Single Cell Unique Dual Indexes Accessory product providing 96 indexes that enable high-plex pooling of up to 96 samples, allowing multiplexing of more than 8 samples per sequencing run for single-cell workflows.
  • Illumina Single Cell Nuclei Isolation Kit Optional accessory reagent kit providing reagents for nuclei isolation, washing, and resuspension to enable single nuclei input into the Illumina Single Cell 3' RNA Prep workflow.
  • Illumina Single Cell Supplemental Enrichment and Amplification Kit Optional accessory reagent kit providing reagents for custom single-cell applications, enabling enrichment of custom RNA tag sequences for expanded multiomic workflows.
  • Illumina Single Cell Prep Starter Equipment One-time purchase equipment bundle required for the Illumina Single Cell Library Prep workflow, including a vortex mixer engineered for consistent emulsification, a dry bath with heated lid, and accessories for 0.5ml, 1.5ml, and 5ml tubes.

Quantifiable outcome

  • Single-cell analysis scalable from 100 to 200,000 cells in a single reaction
  • +3 more outcomes

Companies that use Fluent BioSciences

Customer profile

Named customers2 records

Segments5 records

Ideal customer profiles4 records

Fluent BioSciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration11 records

Feature4 records

Fluent BioSciences partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship and core.

  • IlluminaflagshipOEM/ Whitelabel/ Licensing Partner · 30 April 2026Following acquisition, Illumina integrated Fluent BioSciences single-cell RNA sequencing into its TruPath Genome platform launched in Taiwan in April 2026, combining single-cell transcriptomics with whole-genome sequencing.
  • IlluminaflagshipOEM/ Whitelabel/ Licensing Partner · 1 July 2024Illumina acquired Fluent BioSciences in July 2024 for less than $120 million to enhance its multiomics portfolio with single-cell technology. The acquisition is part of Illumina's broader strategy to expand in the single-cell sequencing space. Fluent BioSciences products are now sold under Illumina's brand as Illumina Single Cell 3' RNA Prep kits.
  • Ultima GenomicscoreTechnology or IntegrationFluent BioSciences received NIH SBIR Phase II grant to commercialize low-cost, high-capacity single-cell RNA sequencing kits enabled by Ultima Genomics' sequencing technology. The partnership combines Fluent BioSciences' PIPseq technology with Ultima Genomics' high-throughput sequencing capabilities.
  • Washington University in St. LouiscoreStrategic or Co-development PartnerWashington University in St. Louis lab successfully tested Fluent BioSciences' prototype million-cell analysis kits, demonstrating the potential of the technology for high-throughput cellular analysis research.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Fluent BioSciences competitors and assessment

Company assessment

Emerging players

  • 1CellBio: Emerging single-cell multiomics player with droplet-based workflows for targeted gene expression and proteogenomics, partially overlapping with PIPseq's transcriptomics applications.
  • Scale Biosciences: Early-stage single-cell company developing low-cost, scalable combinatorial indexing-based workflows; directly comparable on the microfluidics-free, cost-accessible thesis.

Direct peers

  • Singleron Biotechnologies: Single-cell sequencing company offering microfluidic-free workflows (AccuraCode, Singleron Matrix) targeting similar academic, clinical, and pharma customers as Fluent/PIPseq.
  • Parse Biosciences: Single-cell RNA sequencing company whose Evercode platform also eliminates microfluidics through combinatorial barcoding. Directly comparable to PIPseq on the microfluidics-free, scalable workflow value proposition.
  • 10x Genomics: Category leader in single-cell sequencing with the Chromium platform, offering microfluidic droplet-based scRNA-seq, multiome, ATAC, and spatial assays. The dominant incumbent Fluent/PIPseq directly competes against on cost, ease-of-use, and scalability.
  • Mission Bio: Single-cell DNA sequencing and multiomics platform (Tapestri) for genomics, particularly oncology. Competes with Fluent in adjacent single-cell applications and shares overlapping pharma/biotech customers.
  • BD (Becton Dickinson) – BD Rhapsody: BD's Rhapsody single-cell analysis platform uses a microwell-based approach to compete with both microfluidic and PIPseq-style workflows. A major strategic competitor for biotech and pharma single-cell deals.

Broad incumbents

  • Bio-Rad Laboratories: Broader life science tools and ddPCR/droplet technology provider with single-cell adjacencies through the ddSEQ workflow, supplying incumbent alternatives for scRNA-seq sample prep.
  • Illumina: Now Fluent's parent company, Illumina provides the NovaSeq/NextSeq sequencing platforms and global commercial infrastructure under which PIPseq is sold as Illumina Single Cell 3' RNA Prep.

Others

  • Element Biosciences: Sequencer vendor whose Aviti platform is documented as compatible with PIPseq chemistry. Acts as an enabling ecosystem partner rather than a direct competitor.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Fluent BioSciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Fluent BioSciences leadership team

Management profile

Number of profiles

Profiles5 records

Fluent BioSciences funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Fluent BioSciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fluent BioSciences

What does Fluent BioSciences do?

Fluent BioSciences develops and sells single-cell RNA sequencing reagent kits and analysis software based on its proprietary PIPseq (Particle-Templated Instant Partitions) technology. The product line includes four kit tiers (T2, T10, T20, T100) supporting 2,000 to 100,000 cells per sample, along with PIPseeker analysis software, multiplexing indexes, nuclei isolation reagents, enrichment kits, and starter equipment such as vortex mixers and dry baths. The platform enables single-cell mRNA capture, barcoding, and library preparation without requiring microfluidic instrumentation.

Is Fluent BioSciences a public or private company?

Fluent BioSciences is a private company. It is classified as corporate owned and is currently acquired.

When was Fluent BioSciences founded?

Fluent BioSciences was founded in 2017. It employs 1 to 10 people.

Where is Fluent BioSciences based?

Fluent BioSciences is headquartered in Watertown, United States, in the North America region.

How does Fluent BioSciences make money?

Three revenue lines are on record. Single-cell RNA sequencing kits are the primary driver. The others are PIPseeker Software and accessory Products.

Who are Fluent BioSciences's main competitors?

Emerging players on record are 1CellBio and Scale Biosciences. Direct peers are Singleron Biotechnologies, Parse Biosciences, 10x Genomics, Mission Bio and BD (Becton Dickinson) – BD Rhapsody. Broad incumbents are Bio-Rad Laboratories and Illumina. Element Biosciences is listed as an others.

Does Fluent BioSciences have an API?

No public API is recorded for Fluent BioSciences.

What industry is Fluent BioSciences in?

Fluent BioSciences's product category is Single-Cell RNA Sequencing Reagents. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays), with a secondary code of HLAGANAE, Transcriptomics & Gene Expression Profiling Services. Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comAnalysis of Key Market Segments Driving the Transcriptomics MarketThe transcriptomics market is projected to reach $10.3 billion by 2030, growing at a compound annual growth rate of 7.8%, driven by AI-powered data analysis tools, personalized therapy demand, and expanded clinical applications. In July 2024, Illumina Inc. acquired Fluent BioSciences Inc. to enhance its multiomics portfolio with single-cell technology, while NanoString Technologies introduced the CosMx 6,000 plex RNA Assay in February 2024 as the first commercial single-cell spatial panel capable of measuring over 6,000 RNA targets.NatureBarriers fall for single-cell sequencingIllumina has made its PIPseq™ single-cell sequencing technology widely available through the Illumina Single Cell Prep kit following its 2024 acquisition of Fluent BioSciences. This microfluidics-free platform aims to democratize access to single-cell analysis by using hydrogel beads to capture up to one million cells with standard lab equipment, reducing reliance on expensive specialized machinery.RedditOmics Solution Provider Market Map : rThe article introduces a comprehensive market map of the Omics Solution Provider landscape, highlighting how these entities transform complex multi-omic technologies into accessible services. It identifies key companies such as Ultima Genomics, AtlasXomics, Fluent Biosciences, and Seqwell that are enabling high-throughput biological discoveries through specialized tools and instruments.PR NewswireMolecular Diagnostics Market to Hit USD 33.7 Billion by 2032, Growing at 7.3% CAGR | SkyQuest Technology ConsultingThe global molecular diagnostics market is valued at USD 19.1 billion in 2024 and is projected to reach USD 33.7 billion by 2032, growing at a 7.3% CAGR, driven by advances in genomic technologies, rising demand for early disease detection, and adoption of personalized medicine. In July 2024, Illumina completed the acquisition of Fluent BioSciences to strengthen its portfolio in high-resolution genomic tools for oncology and immunology applications. In May 2024, Bruker Corporation completed the €870 million acquisition of ELITechGroup, positioning itself as an innovative infectious disease company in the IVD industry.YahooGlobal Microfluidics Market Size Projected to Reach USD 92.43 Billion by 2032, Driven by Diagnostics, Personalized Medicine, and AI Integration | Research by S&S InsiderThe global microfluidics market is projected to grow from USD 27.86 billion in 2023 to USD 92.43 billion by 2032, representing a compound annual growth rate of 14.29%, driven by demand for diagnostics, personalized medicine, and AI integration. North America dominated the market with 42% share in 2023, while Asia-Pacific is forecast to grow at the fastest rate of 17.48% CAGR through 2032. Key industry developments include Illumina's acquisition of Fluent BioSciences in July 2024 and Bio-Rad's launch of Celselect Slides 2.0 for liquid biopsy applications.PR NewswireGenomics Personalized Health Market to reach US$ 33 Billion by 2034, Driven by Advances in Next-Generation Sequencing - Transparency Market Research, Inc.Transparency Market Research published a report projecting the global genomics personalized health market to reach US$ 33 billion by 2034, growing at a compound annual growth rate of 12.2% from a 2024 valuation of US$ 10.2 billion. The market expansion is driven by advances in next-generation sequencing technologies, AI and machine learning integration, and increasing demand for early disease diagnosis and preventive healthcare. Notable recent acquisitions in the sector include Illumina Inc.'s purchase of Fluent BioSciences (July 2024) and Invitae Corp.'s acquisition of Ciitizen (September 2021), reflecting strategic consolidation among genomic research and diagnostics companies.Business InsiderIllumina’s Strategic Acquisition of Fluent Biosciences: Bolstering Market Dominance in Single Cell SequencingLeerink Partners and Citi both gave a Buy rating on Illumina on July 10, citing its acquisition of Fluent Biosciences. The deal strengthens Illumina's single-cell sequencing position and could pressure 10x Genomics. Illumina's stock fell 23.66% over six months, from $139.74 to $106.68.World Pharmaceutical FrontiersIllumina acquires Fluent BioSciences to boost single-cell analysisIllumina has completed the acquisition of Fluent BioSciences to integrate its PIPseq V single-cell analysis technology into its product portfolio. This strategic move aims to eliminate barriers associated with complex instrumentation, enabling more accessible and scalable single-cell research for customers. Illumina plans to leverage this technology to develop full end-to-end multiomics solutions while maintaining its existing partnerships.MedTech DiveIllumina buys Fluent Biosciences, adding single-cell analysis techIllumina has acquired Fluent Biosciences to integrate its single-cell analysis technology into its product portfolio, marking a strategic expansion into the single-cell sequencing market. The acquisition adds Fluent's cost-effective kits, which compete with offerings from partners like 10x Genomics and rivals such as BD, to Illumina's existing lineup. While specific financial terms were not disclosed, analysts estimate Fluent's revenue base is likely under $10 million.